齐鲁创新研发国际化进程加快推进，两个多月来，有4款齐鲁制药创新药获得美国食品药品监督管理局（FDA）授予的新药临床试验（IND）默示许可。其中，注射用QLS4131、QLS12010胶囊、QLS1304片首次获得FDA临床试验许可，QLC1101胶囊 ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

1Janssen Research and Development, Spring House, Pennsylvania. *Corresponding Author: Bethany K. Mattson Cypert, Oncology, Janssen, Pharmaceutical Companies of Johnson and Johnson, 1400 McKean Road, ...

1Department of Otolaryngology—Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota. 2Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota.

A trio of House Democrats asked to be removed as co-sponsors of a resolution to impeach President Trump, a sign that many in the party do not want to go down the path of trying to remove the presi ...

This review explores the role of PET in imaging immune activation, particularly in oncology. 18F-FDG is widely used for assessing treatment response to immunotherapies and can demonstrate unique ...

Enhancing wheat plants' sugar signaling ability could deliver increased yields of up to 12%, according to researchers from Rothamsted, Oxford University and the Rosalind Franklin Institute ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster ...

Pro-inflammatory pathways dampen the response to treatments, including immune checkpoint inhibitors, necessitating therapies that target this inflammatory signaling network in the TIME. One of the ...

ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-cell engager co-developed with Celltrion, is engineered to selectively target HER2-overexpressing tumors while reducing the risk of on-target ...